1-10 of 10
Keri R. Maher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Retrospective Comparison of Hypomethylating Agent in Combination with Venetoclax Versus Liposomal Daunorubicin and Cytarabine in Frontline Treatment of Acute Myeloid Leukemia

Keri R. Maher, Ian M. Bouligny
Journal: Blood
Blood (2021) 138 (Supplement 1): 2336.
https://doi.org/10.1182/blood-2021-153918
Published: 2021
Journal Articles

Outcomes of Induction with Venetoclax in Combination with Decitabine, Azacitidine, or Low-Dose Cytarabine for Treatment of AML: A Real-World Retrospective Analysis

Ian M. Bouligny, Keri R. Maher
Journal: Blood
Blood (2021) 138 (Supplement 1): 2335.
https://doi.org/10.1182/blood-2021-153738
Published: 2021
Journal Articles

Minority Health Disparities in Acute Myeloid Leukemia: A Metropolitan, Single-Center Retrospective Analysis

Keri R. Maher, Ian M. Bouligny
Journal: Blood
Blood (2021) 138 (Supplement 1): 1987.
https://doi.org/10.1182/blood-2021-153642
Published: 2021
Journal Articles

Differential Outcomes of Salvage with FLAG-IDA and Venetoclax-Based Regimens in Relapsed and Refractory Acute Myeloid Leukemia

Ian M. Bouligny, Keri R. Maher
Journal: Blood
Blood (2021) 138 (Supplement 1): 4424.
https://doi.org/10.1182/blood-2021-153690
Published: 2021
Journal Articles

The Impact of Molecular and Cytogenetic Clonal Evolution on Survival in Relapsed/Refractory AML

Ian M. Bouligny, Keri R. Maher
Journal: Blood
Blood (2021) 138 (Supplement 1): 4452.
https://doi.org/10.1182/blood-2021-153194
Published: 2021
Journal Articles

Outcomes of High-Intensity Versus Low-Intensity Induction in Elderly Patients with AML: A Retrospective Analysis of Real-World Outcomes

Ian M. Bouligny, Keri R. Maher
Journal: Blood
Blood (2021) 138 (Supplement 1): 4386.
https://doi.org/10.1182/blood-2021-153526
Published: 2021
Journal Articles

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Leila Jafari, Jubair Hussain, Ravi Krishnadasan, MD, Keri R Maher, DO, Faiz Anwer, MD, Emad Elquza, MD MBA, Christopher Campen, PharmD, Lauren Sanders, PharmD, Alyssa Henglefelt, PharmD, Alicia Ortega, PharmD, Ali McBride, PharmD,MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2153.
https://doi.org/10.1182/blood-2019-132121
Published: 2019
Journal Articles

Survival Benefit of Novel Drug Combinations Using Hypomethylating Agents for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Systemic Review

Pavan Tenneti, MD, Keri R Maher, DO, Mohamed Mokhtar Bakr, MD, Umar Zahid, MD MPH, Saad Ullah Malik, MD, Warda Faridi, MD, Faiz Anwer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5182.
https://doi.org/10.1182/blood-2018-99-115810
Published: 2018
Journal Articles

Elderly AML: A Five-Year Retrospective Review on Prognostic Features

Akshay Amaraneni, MD, Jennifer Segar, MD, Trace Bartels, BS, Onyemaechi Okolo, MD, Andrew C Rettew, DO, Ali McBride, PharmD, MS, Faiz Anwer, MD, Keri R Maher, DO
Journal: Blood
Blood (2018) 132 (Supplement 1): 5187.
https://doi.org/10.1182/blood-2018-99-111418
Published: 2018
Journal Articles

Safety and Efficacy of Plerixafor on a Convenient Dose Schedule to Facilitate Outpatient Hematopoietic Stem Cell Collection for Autologous Hematopoietic Transplantation

Christopher Chen, MD MBA, Andrew M. Yeager, MD, Faiz Anwer, MD, Ali McBride, PharmD, MS, Keri R Maher, DO, Christopher Campen, PharmD
Journal: Blood
Blood (2016) 128 (22): 5736.
https://doi.org/10.1182/blood.V128.22.5736.5736
Published: 2016